Comparative Effectiveness of Second-Line Antihyperglycemic Agents for Cardiovascular OutcomesRohan Khera, Patrick B. Ryan, Tara V. Anand et al.|Journal of the American College of Cardiology|2024Cited by 33
Similar Risk of Kidney Failure among Patients with Blinding Diseases Who Receive Ranibizumab, Aflibercept, and BevacizumabCindy X. Cai, Patrick Ryan, Anthony G. Sena et al.|Ophthalmology Retina|2024Cited by 16